Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 23Thoracic 15Breast 10Head & Neck 6Genitourinary 4Sarcoma 3Gynecologic 3Endocrine 3Tumor-Agnostic 2NET 2Dermatologic 2CNS 2Plasma cell 1Other solid neoplasm 1Lymphoid 1

Conditions

Neuroendocrine Tumors 2Multiple Endocrine Neoplasia Type 2a 1Lung Neoplasms 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liquid Biopsy × Endocrine × Clear all
NCT05255133 2025-01-06

Liquid-NET

Universiteit Antwerpen

Phase NA Completed
22 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06081270 2023-10-13

MUT-ONC

University of Milano Bicocca

Unknown
20 enrolled
EndocrineThoracic

Lung Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT05268952 2022-03-07

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

University Hospital, Antwerp

Phase NA Unknown
100 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡